ARTICLE | Company News
Aeterna, Ferrer, Schering sales and marketing update
February 20, 2001 8:00 AM UTC
Ferrer received exclusive commercialization and distribution rights to AEL's Neovastat (AE-941) oral blocker of angiogenesis in Spain, Greece, Portugal and Italy. Separately, Schering's Medac GmbH su...